Trastuzumab re-treatment following adjuvant trastuzumab and the importance of distant disease-free interval: the HERA trial experience

This retrospective analysis conducted using data from patients enrolled onto the Herceptin Adjuvant has two objectives: The first is to evaluate the impact of the time interval between the end of adjuvant trastuzumab and distant recurrence (TDRI) upon overall survival (OS). The second is to describe...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Breast Cancer Res Treat
Autores principales: Metzger-Filho, Otto, de Azambuja, Evandro, Procter, Marion, Krieguer, Magalie, Smith, Ian, Baselga, Jose, Cameron, David, Untch, Michael, Jackisch, Christian, Bell, Richard, Gianni, Luca, Goldhirsch, Aron, Piccart, Martine, Gelber, Richard D.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2015
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4947530/
https://ncbi.nlm.nih.gov/pubmed/26708471
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-015-3656-0
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares